ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 반려동물 진단 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 21.5%, 시장 규모는 190억 7,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 표적요법 개발, 감염증 진단, 희귀질환 진단 증가, 바이오마커에 기초한 의약품 개발 증가, 포인트 오브 케어 검사, 리퀴드 바이옵시 응용에 기인하는 것으로 예상됩니다. 예측기간의 주요 동향에는 면역요법과 면역학의 진보, 진단학에서의 AI와 머신러닝, 제품 이노베이션, Industry 4.0의 채용, 전략적 제휴 등이 포함됩니다.
표적 요법 증가는 반려동물 진단 시장의 성장을 가속할 것으로 예상됩니다. 표적요법이란 암세포의 특정 특징에 초점을 맞추고 질병의 성장과 확대를 늦추는 약리학적 접근을 말합니다. 이 약은 전신을 순환하지만 화학 요법보다 정확한 효과가 있으며 부작용이 적습니다. 생물학적 마커를 기반으로 한 반려동물 진단 검사는 개별화 암 치료의 중요한 요소가되고 있습니다. 예를 들어, 2024년 2월 미국에 본사를 둔 병원·건강 관리 조직인 맞춤형 의료 연합(Personalised Medicine Coalition)은 FDA가 희귀질환 환자에 대한 새로운 개인화 치료를 2022년 6건에 대해 2023년에는 16건 승인했다고 보고했습니다. 그 결과, 표적 요법 증가가 반려동물 진단 시장의 성장에 박차를 가하고 있습니다.
반려동물 진단 시장의 성장은 만성 질환의 유병률 증가에 의해 더욱 촉진됩니다. 반려동물 진단은 만성 질환과 비감염성 질환(NCDs)에서 치료 계획의 조정, 질병 진행의 모니터링, 약물 내성의 예측에 사용되는 경우가 많습니다. 세계보건기구(WHO)의 보고에 따르면 세계 사망자 수의 74%(4,100만 명)에 해당하는 연간 4,100만 명이 NCD에 의해 유발되었습니다. 특히 심혈관질환, 암, 만성호흡기질환, 당뇨병 등의 질병이 이 부담에 크게 기여하고 있습니다. 만성 질환의 이환율 증가는 환자의 예후를 개선하고 시장 전체의 성장에 기여하기 위해 동반자 진단이 필수적인 역할을 담당한다는 것을 강조합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시 경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 반려동물 진단 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업의 분석
세계 반려동물 진단 시장의 성장률 분석
세계의 반려동물 진단 시장 실적 : 규모와 성장, 2019-2024년
세계의 반려동물 진단 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 반려동물 진단 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 반려동물 진단 시장 : 제품과 서비스별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
분석, 키트, 시약
소프트웨어 및 서비스
세계의 반려동물 진단 시장 : 기술별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
중합효소 연쇄반응
차세대 시퀀싱
In Situ 하이브리드화
면역조직화학
세계의 반려동물 진단 시장 : 적응증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
폐암
유방암
대장암
백혈병
악성 흑색종
세계의 반려동물 진단 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제약·바이오 의약품 기업
레퍼런스 랩
수탁연구기관
세계의 반려동물 진단 시장 : 어세이의 서브 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
중합효소 연쇄반응(PCR) 분석
면역조직화학(IHC) 분석
차세대 시퀀싱(NGS) 분석
In-situ hybridization(ISH) 분석
세계의 반려동물 진단 시장 : 키트 및 시약의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
진단 키트
검출 시약
컨트롤 시약
세계의 반려동물 진단 시장 : 소프트웨어 및 서비스의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
데이터 분석 소프트웨어
해석 소프트웨어
커스텀 개발 서비스
컨설팅 및 지원 서비스
제7장 지역별·국가별 분석
세계의 반려동물 진단 시장 :지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 반려동물 진단 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
반려동물 진단 시장 : 경쟁 구도
반려동물 진단 시장 : 기업 프로파일
F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
Abnova Corp.
Amoy Diagnostics Co. Ltd.
ARUP Laboratories
Bayer AG
Biomerieux SA
Danaher Corporation
Guardant Health Inc.
Illumina Inc.
Myriad Genetics Inc.
Siemens Healthcare GmbH
Almac Group
Caris Life Sciences
Cepheid Inc.
Diaceutics plc
Epic Sciences Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 시장의 최근 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
반려동물 진단 시장 2029년 - 가장 새로운 기회를 제공하는 국가
반려동물 진단 시장 2029년 - 가장 새로운 기회를 제공하는 부문
반려동물 진단 시장 2029년 - 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.
The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.
The companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The companion diagnostics market size has grown rapidly in recent years. It will grow from $7.34 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increased adoption of personalized medicine, growth of oncology and cancer therapies, increased pharmaceutical r&d collaboration, precision medicine initiatives, and biomarker discovery.
The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to targetedTherapy development, infectious disease diagnostics, increasing rare disease diagnostics, increasing biomarker-based drug development, point-of-care testing, and liquid biopsy applications. Major trends in the forecast period include immunotherapy and immunology advances, ai and machine learning in diagnostics, product innovations, adoption of industry 4.0, strategic collaborations.
The rising number of targeted therapies is anticipated to drive the growth of the companion diagnostics market. Targeted therapy refers to a pharmacological approach that focuses on specific characteristics of cancer cells to slow down the disease's growth and spread. While these medications circulate throughout the body, they have a more precise effect than chemotherapy and often result in fewer side effects. Companion diagnostic testing based on biological markers is becoming a crucial component of personalized cancer care. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six in 2022. Consequently, the increase in targeted therapies is fueling growth in the companion diagnostics market.
The growth of the companion diagnostics market is further propelled by the rising prevalence of chronic diseases. Companion diagnostics are increasingly used in chronic diseases or non-communicable diseases (NCDs) to tailor treatment plans, monitor disease progression, and predict drug resistance. The World Health Organization reported that 74% of global deaths, equivalent to 41 million, are caused by NCDs annually. Notably, diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The rising incidence of chronic diseases underscores the essential role of companion diagnostics in enhancing patient outcomes and contributing to the overall growth of the market.
A key trend in the companion diagnostics market is technological advancement, particularly the integration of artificial intelligence (AI). AI is being leveraged to develop more efficient drugs and advance companion diagnostics. The extensive genetic profiling data sets, continuously generated, enable the application of AI to identify insights into disease causes. For example, Toronto-based start-up Deep Genomics is utilizing AI to expedite the discovery of better medications for genetic illnesses. Through deep learning, scientists can explore the human genome, analyze billions of chemical compounds, and identify promising formulations for clinical trials. This application of AI in companion diagnostics aligns with the broader trend of technological innovation, driving advancements in the field.
Major players in the companion diagnostics market are joining forces to create innovative treatment solutions aimed at enhancing personalized medicine, improving patient outcomes, and optimizing the effectiveness of targeted therapies. This collaboration among companies will accelerate the development and commercialization of companion diagnostics (CDx) for hematology and oncology treatments. For instance, in January 2024, Agilent Technologies, Inc., a California-based company providing instruments, software, services, and consumables for laboratories, announced a partnership with Incyte, a US-based pharmaceutical company. This collaboration combines Agilent's expertise and established track record in developing companion diagnostics (CDx) to support Incyte's hematology and oncology portfolio. As a result, Agilent will expand its CDx portfolio with new biomarkers, while Incyte will leverage Agilent's proficiency in assay development, regulatory approvals, and commercialization to facilitate clinical trials and CDx registration in the U.S. and Europe.
In August 2022, Genome Diagnostics, a UK-based testing company that offers personalized health insights to assist with diagnosis, treatment, and drug discovery, acquired Eurobio Scientific for USD 148.22 million. This acquisition allows GenDx to broaden its global presence, strengthen customer support in transplant diagnostics, and sustain its R&D and educational initiatives. Eurobio Scientific is a France-based company specializing in the research, development, and marketing of diagnostic products and life-science research products.
Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.
North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The companion diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product And Service: Assays, Kits And Reagents; Software And Services
2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; In Situ Hybridization; Immunohistochemistry
3) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Melanoma
4) By End-User: Pharmaceutical And Biopharmaceutical Companies; Reference Laboratories; Contract Research Organizations
Subsegments:
1) By Assays: Polymerase Chain Reaction (PCR) Assays; Immunohistochemistry (IHC) Assays; Next-Generation Sequencing (NGS) Assays; In Situ Hybridization (ISH) Assays
2) By Kits And Reagents: Diagnostic Kits; Detection Reagents; Control Reagents
3) By Software And Services: Data Analysis Software; Interpretation Software; Custom Development Services; Consulting and Support Services
Companies Mentioned: F Hoffmann-La Roche Ltd.; Agilent Technologies Inc.; Qiagen NV; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Companion Diagnostics Market Characteristics
3. Companion Diagnostics Market Trends And Strategies
4. Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Companion Diagnostics Growth Analysis And Strategic Analysis Framework
5.1. Global Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Companion Diagnostics Market Growth Rate Analysis
5.4. Global Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Companion Diagnostics Total Addressable Market (TAM)
6. Companion Diagnostics Market Segmentation
6.1. Global Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Assays, Kits And Reagents
Software And Services
6.2. Global Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction
Next-Generation Sequencing
In Situ Hybridization
Immunohistochemistry
6.3. Global Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
6.4. Global Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical And Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
6.5. Global Companion Diagnostics Market, Sub-Segmentation Of Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction (PCR) Assays
Immunohistochemistry (IHC) Assays
Next-Generation Sequencing (NGS) Assays
In Situ Hybridization (ISH) Assays
6.6. Global Companion Diagnostics Market, Sub-Segmentation Of Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Kits
Detection Reagents
Control Reagents
6.7. Global Companion Diagnostics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Data Analysis Software
Interpretation Software
Custom Development Services
Consulting and Support Services
7. Companion Diagnostics Market Regional And Country Analysis
7.1. Global Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
